Previous 10 | Next 10 |
Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data Demonstrate AT-527’s Rapid and Potent Antiviral Activity Against COVID-19 in Phase 2 ...
Pfizer's PAXLOVID dominates other COVID-19 antivirals. Big Pharma and Wall Street are recognizing the shortfalls of vaccines and the need for therapeutics. Merck and others fall short of the new competition, but could get back in the race with bolt-on acquisitions or licensing of ...
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, November 11, 2021 at 4:30 p.m. ET to report financi...
Part of being a skilled biotech investor is knowing when discretion is the better part of valor. When bad clinical trial results roll in, your favorite holding might get roiled -- and it might not have enough momentum to ever recover. By the same token, if you're willing to bet on biotechs ...
Look out below for these tumbling biotech stocks. Shares of Atea Pharmaceuticals (NASDAQ: AVIR) , Omeros (NASDAQ: OMER) , and Novavax (NASDAQ: NVAX) were big winners for investors this year right up until they weren't. When stocks fall, they tend to fall hard. Fo...
Atea Pharmaceuticals (NASDAQ: AVIR) didn't get the outcome it wanted with a phase 2 study of its oral antiviral therapy AT-527. In this Motley Fool Live video recorded on Oct. 20 , Motley Fool contributors Keith Speights and Brian Orelli discuss how Atea's clinical flop...
Halloween is coming, but our Fool.com contributors have been wearing masks for a while. Will these vaccine stocks lead us out of the pandemic? This roundtable explores Novavax (NASDAQ: NVAX) , Johnson & Johnson (NYSE: JNJ) , and Atea Pharmaceuticals (NASDAQ: AV...
This month, as Merck (NYSE: MRK) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19, Atea Pharmaceuticals (NASDAQ: AVIR) stock saw a significant drop. Unfortunately, investors are unlikely to see the small-cap biotech repli...
Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF . Risk-tolerant growth investors ap...
Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence . The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-52...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...